Professor Hazel Squires

All publications

Journal articles

• Squires H, Gillespie D, Kock L, Hock E, Hiscock R, Bogdanovica I, Lewis C, Robson D, Filippidis F, Langley T , Pulsford E et al (2025) Scoping of policy impacts for regulating e-cigarettes (SPIRE): findings from a data and decision analytic model mapping project. NIHR Open Research. View this article in WRRO
• West R, Brown J, Shahab L, Baird H, Webb T, Squires H, Tattan-Birch H, Gillespie D, Purshouse R, Brennan A , Mazumdar S et al (2025) Annotating datasets in behavioural and social sciences to promote interoperability: development of the schema for ontology-based dataset annotation (SODA) version 1.0. Wellcome Open Research, 10, 455-455. View this article in WRRO
• Kwon J, Squires H & Young T (2025) Efficiency and equity of community-based falls prevention pathways: a model-based health economic evaluation. Age and Ageing, 54(8). View this article in WRRO
• Bright S, Buckley C, Holman D, Squires H, Greene N, Mulia N, Kilian C, Probst C, Angus C, Holmes J , Constante HM et al (2025) Applying an intersectional lens to alcohol inequities: a conceptual framework. Addiction. View this article in WRRO
• Jackson SE, Squires H, Shahab L, Tattan-Birch H, Buckley C, Purshouse RC & Brown J (2025) Associations of close social connections with smoking and vaping: a population study in England. Nicotine and Tobacco Research, 27(3), 447-456. View this article in WRRO
• Squires H, Kelly MP, Gilbert N, Sniehotta F, Purshouse RC, Garcia L, Breeze P, Brennan A, Gardner B, Bright S , Fischer A et al (2024) The PHEM-B toolbox of methods for incorporating the influences on behaviour into public health economic models. BMC Public Health, 24(1). View this article in WRRO
• Kwon J, Squires H & Young T (2024) Incorporating frailty to address the key challenges to geriatric economic evaluation. BMC Geriatrics, 24(1). View this article in WRRO
• Moore E, Pryce R, Squires H & Goyder E (2024) The association between health-related quality of life and problem gambling severity: a cross-sectional analysis of the Health Survey for England. BMC Public Health, 24(1). View this article in WRRO
• Squires H, Mason S, O'Keeffe C, Croft S & Millington G (2023) What impact would reducing low-acuity attendance have on emergency department length of stay? A discrete event simulation modelling study. Emergency Medicine Journal, 41(1). View this article in WRRO
• Squires H, Jankovic D & Bojke L (2023) Reflecting parameter uncertainty in addition to variability in constrained healthcare resource discrete event simulations: worth going the extra mile or a road to nowhere?. Value in Health, 26(12), 1738-1743. View this article in WRRO
• Squires H, Kelly MP, Gilbert N, Sniehotta F & Purshouse RC (2023) The long‐term effectiveness and cost‐effectiveness of public health interventions; how can we model behavior? A review. Health Economics, 32(12), 2836-2854. View this article in WRRO
• Breeze PR, Squires H, Ennis K, Meier P, Hayes K, Lomax N, Shiell A, Kee F, de Vocht F, O’Flaherty M , Gilbert N et al (2023) Guidance on the use of complex systems models for economic evaluations of public health interventions. Health Economics, 32(7), 1603-1625. View this article in WRRO
• Kwon J, Squires H & Young T (2023) Economic model of community-based falls prevention: seeking methodological solutions in evaluating the efficiency and equity of UK guideline recommendations. BMC Geriatrics, 23(1).
• Kwon J, Squires H, Franklin M & Young T (2022) Systematic review and critical methodological appraisal of community-based falls prevention economic models. Cost Effectiveness and Resource Allocation, 20(1). View this article in WRRO
• Smith R, Thomas C, Squires H & Goyder E (2022) A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool. Wellcome Open Research, 7. View this article in WRRO
• Kwon J, Squires H, Franklin M, Lee Y & Young T (2022) Economic evaluation of community-based falls prevention interventions for older populations : a systematic methodological overview of systematic reviews. BMC Health Services Research, 22(1).
• Kwon J, Squires H, Franklin M, Lee Y & Young T (2022) Economic models of community-based falls prevention: a systematic review with subsequent commissioning and methodological recommendations. BMC Health Services Research, 22(1). View this article in WRRO
• Smith R, Thomas C, Squires H & Goyder E (2022) A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool [under peer review]. Wellcome Open Research, 7(2022). View this article in WRRO
• Kwon J, Lee Y, Young T, Squires H & Harris J (2021) Qualitative research to inform economic modelling : a case study in older people’s views on implementing the NICE falls prevention guideline. BMC Health Services Research, 21(1). View this article in WRRO
• Smith R, Thomas C, Squires H, Götschi T, Kahlmeier S & Goyder E (2021) The price of precision: trade-offs between usability and validity in the World Health Organization Health Economic Assessment Tool for walking and cycling. Public Health, 194, 263-269. View this article in WRRO
• Gillespie D, Hatchard J, Squires H, Gilmore A & Brennan A (2021) Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system. BMC Public Health, 21. View this article in WRRO
• Thomas C, Brennan A, Goka E, Squires H, Brenner G, Bagguley D, Buckley Woods H, Gillett M, Leaviss J, Clowes M , Heathcote L et al (2020) What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation. BMJ Open, 10(9). View this article in WRRO
• Squires H, Bermejo I, Poku EN, Cooper K, Stevens J, Hamilton J, Wong R, Denniston AK, Pearce I & Quhill FM (2019) Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 103(11), 1639-1644. View this article in WRRO
• Bermejo I, Squires H, Poku EN, Cooper K, Stevens JW, Hamilton J, Wong R, Pearce I, Quhill FM & Denniston AK (2019) Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 103(11), 1633-1638. View this article in WRRO
• Ren S, Squires H, Hock E, Kaltenthaler E, Rawdin A & Alifrangis C (2019) Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 37(9), 1073-1080. View this article in WRRO
• Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R & Wyld L (2018) Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics, 36(1), 29-38.
• Squires HY, Poku E, Bermejo I, Cooper K, Stevens J, Hamilton J, Wong R, Denniston A, Pearce I & Quhill F (2017) A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate, posterior or panuveitis in adults. Health Technology Assessment , 21(68). View this article in WRRO
• Thomas C, Sadler S, Breeze P, Squires H, Gillett M & Brennan A (2017) Assessing the Potential Return on Investment of the Proposed UK NHS Diabetes Prevention Programme in Different Population Subgroups: An Economic Evaluation. BMJ Open, 7. View this article in WRRO
• Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, Fischer A & Chilcott J (2017) A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of Epidemiology and Community Health, 71, 897-904. View this article in WRRO
• Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle P, Brunner E, Tabak A, Preston L & Chilcott J (2017) Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK.. Diabetic Medicine, 34(8), 1136-1144. View this article in WRRO
• Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, Brunner E, Tabak A, Preston L & Chilcott J (2017) The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis.. Diabetic Medicine, 34(5), 632-640. View this article in WRRO
• Breeze P, Squires H, Chilcott J, Stride C, Diggle PJ, Brunner E, Tabak A & Brennan A (2016) A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study. Journal of Public Health, 38(4), 679-687.
• Squires H, Chilcott J, Akehurst R, Burr J & Kelly MP (2016) A Framework for Developing the Structure of Public Health Economic Models. Value in Health, 19(5), 588-601. View this article in WRRO
• Squires H, Stevenson M, Simpson E, Harvey R & Stevens J (2016) Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(7), 673-680. View this article in WRRO
• Squires H, Chilcott J, Akehurst R, Burr J & Kelly MP (2016) A systematic literature review of the key challenges for developing the structure of public health economic models. International Journal of Public Health, 61(3), 289-298.
• (2016) Retracted: Impact of Type 2 diabetes prevention programmes based on risk identification and lifestyle intervention intensity strategies: a cost‐effectiveness analysis. Diabetic Medicine, 33(8), 1155-1163.
• Watson P, Preston L, Squires H, Chilcott J & Brennan A (2014) Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods.. Appl Health Econ Health Policy, 12(3), 239-253.
• Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G & O'Donnell ME (2014) Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.. Angiology, 65(3), 190-197.
• Stevenson M, Tappenden P & Squires H (2014) Methods for handling uncertainty within pharmaceutical funding decisions. International Journal of Systems Science, 45(1), 60-68.
• Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J & Stansby G (2013) Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).. Br J Surg, 100(13), 1838-1839.
• Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health.
• Squires H, Chilcott J, Akehurst R & Burr J (2012) Guidance for modellers for developing public health economic models. The Lancet, 380, S68-S68.
• Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.. Value Health, 15(8), 1127-1136.
• Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J & Stansby G (2012) Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery, 99(12), 1630-1638.
• Turner RM, Lloyd-Jones M, Anumba DOC, Smith GCS, Spiegelhalter DJ, Squires H, Stevens JW, Sweeting MJ, Urbaniak SJ, Webster R & Thompson SG (2012) Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: Meta-analyses adjusted for differences in study design and quality. Plos One, 7(2).
• Squires H, Rick J, Carroll C & Hillage J (2012) Cost-effectiveness of interventions to return employees to work following long-term sickness absence due to musculoskeletal disorders.. J Public Health (Oxf), 34(1), 115-124.
• Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J & Stansby G (2011) A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.. Health Technol Assess, 15(40), 1-210.
• Squires H, Tappenden P, Cooper K, Carroll C, Logan R & Hind D (2011) Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. Clinical Therapeutics, 33(9), 1289-1305.
• Bujkiewicz S, Jones HE, Lai MCW, Cooper NJ, Hawkins N, Squires H, Abrams KR, Spiegelhalter DJ & Sutton AJ (2011) Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care. Value in Health, 14(5), 768-776.
• Baxter S, Blank L, Guillaume L, Squires H & Payne N (2011) Views of contraceptive service delivery to young people in the UK: a systematic review and thematic synthesis.. J Fam Plann Reprod Health Care, 37(2), 71-84.
• Baxter S, Blank L, Guillaume L, Squires H & Payne N (2011) Views regarding the use of contraception amongst young people in the UK: a systematic review and thematic synthesis.. Eur J Contracept Reprod Health Care, 16(3), 149-160.
• Papaioannou D, Cooper KL, Carroll C, Hind D, Squires H, Tappenden P & Logan RF (2011) Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis.. Colorectal Dis, 13(10), 1085-1099.
• Blank L, Baxter SK, Payne N, Guillaume LR & Pilgrim H (2010) Systematic review and narrative synthesis of the effectiveness of contraceptive service interventions for young people, delivered in educational settings.. J Pediatr Adolesc Gynecol, 23(6), 341-351.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England. International Journal of Technology Assessment in Health Care, 26(4), 362-369.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England.. Int J Technol Assess Health Care, 26(4), 362-369.
• Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D & Tappenden P (2010) Chemoprevention of colorectal cancer: systematic review and economic evaluation.. Health Technol Assess, 14(32), 1-206.
• Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H & Tappenden P (2010) Supplemental Calcium in the Chemoprevention of Colorectal Cancer: A Systematic Review and Meta-Analysis. CLIN THER, 32(5), 789-803.
• Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H & Booth A (2010) Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer.. Aliment Pharmacol Ther, 31(7), 708-718.
• Baxter SK, Blank L, Payne N, Guillaume LR & Pilgrim H (2010) Systematic review and narrative synthesis of the effectiveness of contraceptive service interventions for young people, delivered in educational settings.. Journal of Pediatric and Adolescent Gynecology.
• Carroll C, Rick J, Pilgrim H, Cameron J & Hillage J (2010) Workplace involvement improves return to work rates among employees with back pain on long-term sick leave: a systematic review of the effectiveness and cost-effectiveness of interventions.. Disabil Rehabil, 32(8), 607-621.
• Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A & Tappenden J (2009) The costs and benefits of bowel cancer service developments using discrete event simulation. J OPER RES SOC, 60(10), 1305-1314.
• Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.. Int J Technol Assess Health Care, 25(4), 470-478.
• Ward S, Pilgrim H & Hind D (2009) Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.. Health Technol Assess, 13 Suppl 1, 1-6.
• Pilgrim H, Lloyd-Jones M & Rees A (2009) Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(10).
• Pilgrim H, Lloyd-Jones M & Rees A (2009) Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health Technol Assess, 13(10), iii-103.
• Pilgrim H, Lloyd-Jones M & Rees A (2009) Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(10).
• Pilgrim H & Chilcott J (2008) Assessment of a 7-day turn-around for the reporting of cervical smear results using discrete event simulation. J OPER RES SOC, 59(7), 902-910.
• Hadwin R, Eggington S, Brennan A, Walker P, Patnick J & Pilgrim H (2008) Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme. BJOG-INT J OBSTET GY, 115(6), 749-757.
• Pilgrim H, Jewitt K & Ward S (2007) A Cost-Utility Analysis of Nilotinib for CML Patients Who Have Become Resistant to Imatinib.. Blood, 110(11), 5175-5175.
• Hind D, Pilgrim H & Ward S (2007) Questions about adjuvant trastuzamab still remain (vol 369, pg 3, 2007). LANCET, 369(9562), 642-642.
• Hind D, Pilgrim H & Ward S (2007) Questions about adjuvant trastuzumab still remain.. Lancet, 369(9555), 3-5.
• Shahab L & Squires H () What tranSPIREs from Recent Research on e-Cigarettes? Towards a Comprehensive Approach to Model Vaping Policies. Nicotine and Tobacco Research.
• Ward S, Pilgrim H & Hind D () Trastuzumab for the treatment of primary HER2-positive breast cancer in HER2-positive women: a single technology appraisal. Health Technology Assessment, 13(Suppl 1), 1-6.

Conference proceedings

• Tian D, Squires H, Buckley C, Gillespie D, Tattan-Birch H, Shahab L, West R, Brennan A, Brown J & Purshouse R (2025) Incorporating the COM-B model for behavior change into an agent-based model of smoking behaviors: an object-oriented design. 2024 Winter Simulation Conference (WSC) (pp 252-263). Orlando, Florida, 15 December 2024 - 15 December 2024. View this article in WRRO
• Thomas C, Watson P, Squires H, Chilcott J & Brennan A (2014) Validation of the SPHR Diabetes Prevention Model. Value in Health, Vol. 17(7) (pp A556-A556)
• Thomas C, Watson P, Greaves C, Squires H, Chilcott J & Brennan A (2014) Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. Value in Health, Vol. 17(7) (pp A347-A347)
• Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G & O'Donnell M (2012) COST-EFFECTIVENESS OF CILOSTAZOL, NAFTIDROFURYL OXALATE, PENTOXIFYLLINE AND INOSITOL NICOTINATE FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN PEOPLE WITH PERIPHERAL ARTERIAL DISEASE IN THE UK. VALUE IN HEALTH, Vol. 15(7) (pp A633-A633)
• Mildred M, Ward S, Squires H & Gray E (2012) Cost-effectiveness analysis of nilotinib versus imatinib for the treatment of chronic phase philadelphia chromosome positive chronic myeloid leukaemia. 17th Congress of EHA. Amsterdam, The Netherlands, 14 June 2012 - 14 June 2012. View this article in WRRO
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS. VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND FOLLOW-UP OF COLORECTAL CANCER. VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
• Jewitt K, Pilgrim H & Ward S (2008) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 141 (pp 38-38)
• Pilgrim H, Jewitt K & Ward S (2007) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.. BLOOD, Vol. 110(11) (pp 376B-376B)
• Meng Y, Squires H, Stevens J, Simpson E, Thomas S, Michaels J, Stansby G & O'Donnell M () Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK (2012)

Reports

• Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle P, Brunner E, Tabak A, Preston L & Chilcott J (2015) SPHR Diabetes Prevention Model: Detailed Description of Model Background, Methods, Assumptions and Parameters View this article in WRRO

Posters

• Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.

Datasets

• Gillespie D, Hatchard J, Squires H, Gilmore A & Brennan A Archived data for ‘Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system’.

Other

• Pilgrim H (2010) Simulation in healthcare Part 2. Journal of Simulation, 4(1), 1.
• Pilgrim H (2009) Simulation in healthcare - Part 1. Journal of Simulation, 3(3), 129-129.

Preprints

• Kwon J, Squires H, Franklin M, Lee MY & Young T (2021) Economic Models of Community-Based Falls Prevention: A Systematic Review With Subsequent Commissioning And Methodological Recommendations, Springer Science and Business Media LLC.
• Kwon J, Squires H, Franklin M, Lee Y & Young T (2021) Economic Evaluation of Community-Based Falls Prevention Interventions: A Systematic Methodological Overview of Systematic Reviews, Research Square Platform LLC.
• Kwon J, Lee Y, Young T, Squires H & Harris J (2021) Qualitative Research to Inform Economic Modelling: Older People’s Views on Implementing the Nice Falls Prevention Guideline in English Community Context., Research Square Platform LLC.
• Kwon J, Lee Y, Squires H, Franklin M & Young T (2021) Economic Evaluation of Community-based Falls Prevention Interventions: a Systematic Methodological Overview of Systematic Reviews, Springer Science and Business Media LLC.